A hemostatic composition includes a carrier medium including a predetermined amount of a particulate material. The particulate material is comprised of core particles with a coating. The core particles have an average particle size of about 5 nm to 10 μm, and the coating is one of gold, silica
A hemostatic composition includes a carrier medium including a predetermined amount of a particulate material. The particulate material is comprised of core particles with a coating. The core particles have an average particle size of about 5 nm to 10 μm, and the coating is one of gold, silica, silver, platinum, steel, cobalt, carbon, a polymer, or a combination thereof.
대표청구항▼
What is claimed is: 1. A hemostatic composition suitable for controlling external or internal bleeding in a subject, comprising: a) a biocompatible and non-toxic carrier medium selected from the group consisting of water, saline solution, sugar solution, Lactose Ringers, blood plasma, and a combina
What is claimed is: 1. A hemostatic composition suitable for controlling external or internal bleeding in a subject, comprising: a) a biocompatible and non-toxic carrier medium selected from the group consisting of water, saline solution, sugar solution, Lactose Ringers, blood plasma, and a combination thereof; b) a predetermined amount of a particulate material in said medium; c) said particulate material comprising core particles with a coating; d) said core particles having an average particle size of about 5 nm to 10 μm; e) the concentration of said particulate material being about 0.1% to 70% (w/w) of the composition; f) said coating comprising procoagulant molecules; and g) said core particles comprise a member selected from the group consisting of iron, iron oxide, cobalt, cobalt oxide, nickel, nickel oxide, and an alloy or a combination thereof; and h) an optional surfactant or dispersant. 2. The composition of claim 1, wherein: a) said core particles have an average particle size of about 10 nm to 1 μm. 3. The composition of claim 1, wherein: a) said core particles have an average particle size of about 10 nm to 300 nm. 4. The composition of claim 1, wherein: a) said core particles comprise a general shape selected from the group consisting of a sphere, a needle, a cube, an oval, irregular, a cylinder, a diamond, and a combination thereof. 5. The composition of claim 1, wherein: a) said core particles comprise clusters. 6. The composition of claim 1, wherein: a) said core particles comprise the general shape of blood platelets. 7. The composition of claim 1, wherein: a) said coating has a thickness of about 1 nm to 1 μm. 8. The composition of claim 1, wherein: a) said coating has a thickness of about 5 nm to 50 nm. 9. The composition of claim 1, wherein: a) said procoagulant molecules are selected from the group consisting of thrombin, Factor VII a, and a combination thereof. 10. The composition of claim 1, wherein: a) said particulate material is non-toxic to bio-cells or biomolecules. 11. A magnetic hemostatic fluid suitable for controlling external or internal bleeding in a subject, comprising: a) a biocompatible and non-toxic carrier fluid selected from the group consisting of water, saline solution, sugar solution, Lactose Ringers, blood plasma, and a combination thereof; b) a predetermined amount of a magnetic particulate material in said carrier fluid; c) said particulate material comprising core particles with a coating having a thickness of about 1 nm to 10 μm; d) said core particles having an average particle size of about 5 nm to 10 μm; e) the concentration of said particulate material being about 0.1% to 70% (w/w) of the hemostatic fluid; f) said core particles comprising a member selected from the group consisting of iron, iron oxide, cobalt, cobalt oxide, nickel, nickel oxide, and an alloy or a combination thereof; g) said coating comprising procoagulant molecules; and h) an optional surfactant or dispersant. 12. The hemostatic fluid of claim 11, wherein: a) said core particles have an average particle size of about 10 nm to 1 μm. 13. The hemostatic fluid of claim 11, wherein: a) said core particles have an average particle size of about 10 nm to 300 nm. 14. The hemostatic fluid of claim 11, wherein: a) said core particles comprise a general shape selected from the group consisting of a sphere, a needle, a cube, an oval, irregular, a cylinder, a diamond, and a combination thereof. 15. The hemostatic fluid of claim 11, wherein: a) said core particles comprise clusters. 16. The hemostatic fluid of claim 11, wherein: a) said core particles comprise the general shape of blood platelets. 17. The hemostatic fluid of claim 11, wherein: a) said coating has a thickness of about 5 nm to 50 nm. 18. The hemostatic fluid of claim 11, wherein: a) said procoagulant molecules are selected from the group consisting of thrombin, Factor VII a, and a combination thereof. 19. The hemostatic fluid of claim 11, wherein: a) said particulate material is non-toxic to bio-cells or biomolecules. 20. The hemostatic fluid of claim 11, wherein: a) the magnetic particles comprise paramagnetic or superparamagnetic particles, or a combination thereof. 21. A method of controlling bleeding in a subject in need thereof, comprising the steps of: a) administering to a subject having internal or external bleeding a predetermined amount of a hemostatic fluid; b) the hemostatic fluid, comprising: i) a biocompatible and non-toxic carrier fluid selected from the group consisting of water, saline solution, sugar solution, Lactose Ringers, blood plasma, and a combination thereof; ii) a predetermined amount of a magnetic particulate material in the fluid; iii) the particulate material comprising core particles with a coating having a thickness of about 1 nm to 10 μm; iv) the core particles having an average particle size of about 5 nm to 10 μm; v) the concentration of the particulate material being about 0.1% to 70% (w/w) of the hemostatic fluid; vi) the core particles comprising a member selected from the group consisting of iron, iron oxide, cobalt, cobalt oxide, nickel, nickel oxide, and an alloy or a combination thereof; vii) the coating comprising; and viii) an optional surfactant or dispersant; c) applying a magnetic field adjacent the site of a lesion causing the bleeding so as to form a cluster of the particulate material for thereby controlling the flow of blood through the lesion. 22. A hemostatic composition suitable for controlling external or internal bleeding in a subject, comprising: a) a carrier medium selected from the group consisting of water, saline solution, sugar solution, Lactose Ringers, blood plasma, and a combination thereof; b) a predetermined amount of a particulate material in said medium; c) said particulate material comprising core particles with a coating; d) said core particles having an average particle size of about 5 nm to 10 μm; e) the concentration of said particulate material being about 0.1% to 70% (w/w) of the composition; f) said coating comprising procoagulant molecules; g) said coating further comprising one polymer member selected from the group consisting of polyethylene glycol, dextran, Tween, sorbitol, mannitol, and a combination thereof; and h) said core particles comprise a member selected from the group consisting of iron, iron oxide, cobalt, cobalt oxide, nickel, nickel oxide, and an alloy or a combination thereof; and i) an optional surfactant or dispersant. 23. A hemostatic composition suitable for controlling external or internal bleeding in a subject, comprising: a) a carrier medium selected from the group consisting of water, saline solution, sugar solution, Lactose Ringers, blood plasma, and a combination thereof; b) a predetermined amount of a particulate material in said medium; c) said particulate material comprising core particles with a coating; d) said core particles having an average particle size of about 5 nm to 10 μm; e) the concentration of said particulate material being about 0.1% to 70% (w/w) of the composition; f) said coating comprising a member biocompatible and non-toxic to blood cells; g) said member comprising procoagulant molecules; and h) said core particles comprise a member selected from the group consisting of iron, iron oxide, cobalt, cobalt oxide, nickel, nickel oxide, and an alloy or a combination thereof; and i) an optional surfactant or dispersant. 24. A hemostatic composition suitable for controlling external or internal bleeding in a subject, comprising: a) a biocompatible and non-toxic carrier medium selected from the group consisting of water, saline solution, sugar solution, Lactose Ringers, blood plasma, and a combination thereof; b) a predetermined amount of a particulate material in said medium; c) said particulate material comprising core particles with a coating; d) said core particles having an average particle size of more than 500 nm to about 10 μm; e) the concentration of said particulate material being about 0.1% to 70% (w/w) of the composition; f) said coating comprising procoagulant molecules; and g) said core particles comprise a member selected from the group consisting of iron, iron oxide, cobalt, cobalt oxide, nickel, nickel oxide, and an alloy or a combination thereof; and h) an optional surfactant or dispersant. 25. The composition of claim 1, wherein: a) said coating further comprises a biocompatible and non-toxic member selected from the group consisting of gold, silica, silver, platinum, steel, cobalt, carbon, a polymer, and a combination thereof. 26. The hemostatic fluid of claim 11, wherein: a) said coating further comprises a biocompatible and non-toxic member selected from the group consisting of gold, silica, silver, platinum, steel, cobalt, carbon, a polymer, and a combination thereof. 27. The method of claim 21, wherein: a) the coating further comprises a biocompatible and non-toxic member selected from the group consisting of gold, silica, silver, platinum, steel, cobalt, carbon, a polymer, and a combination thereof. 28. The composition of claim 23, wherein: a) said coating further comprises a member selected from the group consisting of gold, silica, silver, platinum, steel, cobalt, carbon, a polymer, and a combination thereof. 29. The composition of claim 24 wherein: a) said coating further comprises a biocompatible and non-toxic member selected from the group consisting of gold, silica, silver, platinum, steel, cobalt, carbon, a polymer, and a combination thereof. 30. The composition of claim 25, wherein: a) said polymer is selected from the group consisting of polyethylene glycol, dextran, Tween, sorbitol, mannitol, and a combination thereof. 31. The hemostatic fluid of claim 26, wherein: a) said polymer is selected from the group consisting of polyethylene glycol, dextran, Tween, sorbitol, mannitol, and a combination thereof.
연구과제 타임라인
LOADING...
LOADING...
LOADING...
LOADING...
LOADING...
이 특허에 인용된 특허 (137)
Krishnan, Mohan; Bowe, Wade A.; Wood, David S.; Hall, Jeffrey A., Ablation catheter with covered electrodes allowing electrical conduction therethrough.
Tay Sew-Wah (Plymouth MN) Schankereli Kemal (Stillwater MN) Holman Thomas (Minneapolis MN) Mische Hans (St. Cloud MN), Apparatus and method for sealing vascular punctures.
Chagnon Mark S. (Lowell MA) Groman Ernest V. (Brookline MA) Josephson Lee (Arlington MA) Whitehead Roy A. (Hingham MA), Binding assays employing magnetic particles.
Siiman Olavi (Davie FL) Burshteyn Alexander (Hialeah FL) Gupta Ravinder K. (Pembroke Pines FL), Biodegradable gelatin-aminodextran particle coatings of and processes for making same.
Groman Ernest V. (Brookline MA) Josephson Lee (Arlington MA) Lewis Jerome M. (Newton MA), Biodegradable superparamagnetic metal oxides as contrast agents for MR imaging.
Groman Ernest V. (Brookline MA) Josephson Lee (Arlington MA), Biologically degradable superparamagnetic particles for use as nuclear magnetic resonance imaging agents.
Czerlinski George H. (9111 Forest View Rd. Evanston IL 60203), Coated magnetizable microparticles, reversible suspensions thereof, and processes relating thereto.
Gureghian Richard S. ; Carlson J. David ; LeRoy Douglas F. ; Marjoram Robert H. ; Brown Matthew B. ; Jolly Mark R., Controllable platform suspension system for treadmill decks and the like and devices therefor.
Kazlas, Peter T.; Hack, Michael G.; Drzaic, Paul S.; Danner, Guy M.; Amundson, Karl R., Fabrication of electronic circuit elements using unpatterned semiconductor layers.
Shtarkman Emil M. (Southfield MI) Starkovich John A. (Redondo Beach CA) Davison William W. (Los Angeles CA) Peng Hsiao-Hu (Los Angeles CA) Fitzgerald Thomas J. (Rossmoor CA), Fluid responsive to a magnetic field.
Seydel Roland ; Luthi Simon ; Fumi Richard,DEX ; Beard Kevin A.,DEX ; Kaiser Ottmar,DEX, Ground-contacting systems having 3D deformation elements for use in footwear.
Takahashi Toru (Shizuoka-ken JPX) Nakamura Hideki (Kanagawa-ken JPX) Goto Katsuya (Fukuoka-ken JPX), High polymer gel and vascular lesion embolizing material comprising the same.
Brown Steven Joseph ; Ingram Larry Stefan ; Messina Neale Arthur ; Tarczynski Marek, Inflator capable of modulation air bag inflation rate in a vehicle occupant restraint apparatus.
Oppenheim ; Richard Charles ; Marty ; Jennifer Joy ; Speiser ; Peter, Injectable compositions, nanoparticles useful therein, and process of manufacturing same.
Schrder Ulf (Fagottgrnden 11 B S-223 68 Lund SEX) Mosbach Klaus (Lackalnga 31 S-244 02 Furulund SEX), Intravascularly administrable, magnetically responsive nanosphere or nanoparticle, a process for the production thereof,.
Chagnon Mark S. (Lowell MA) Groman Ernest V. (Brookline MA) Josephson Lee (Arlington MA) Whitehead Roy A. (Hingham MA), Magnetic particles for use in separations.
Whitehead Roy A. (Hingham MA) Chagnon Mark S. (Lowell MA) Groman Ernest V. (Brookline MA) Josephson Lee (Arlington MA), Magnetic particles for use in separations.
Truong Jack G. ; Wood Thomas E., Magnetic recording media prepared from magnetic particles having an extremely thin, continuous, amorphous, aluminum hydrous oxide coating.
Weiss Keith D. ; Carlson J. David ; Nixon Donald A., Method and magnetorheological fluid formulations for increasing the output of a magnetorheological fluid.
Weiss Keith D. ; Carlson J. David ; Nixon Donald A., Method and magnetorheological fluid formulations for increasing the output of a magnetorheological fluid device.
Bruxvoort Wesley J. ; Culler Scott R. ; Ho Kwok-Lun ; Kaisaki David A. ; Kessel Carl R. ; Klun Thomas P. ; Kranz Heather K. ; Messner Robert P. ; Webb Richard J. ; Williams Julia P., Method of modifying an exposed surface of a semiconductor wafer.
Kresse Mayk (Berlin DEX) Lawaczeck Rudiger (Berlin DEX) Pfefferer Detlef (Berlin DEX), Nanocrystalline magnetic iron oxide particles-method for preparation and use in medical diagnostics and therapy.
Borrelli Nicholas F. (Elmira NY) Luderer Albert A. (Corning NY) Panzarino Joseph N. (Big Flats NY), Radio frequency induced hyperthermia for tumor therapy.
Borrelli Nicholas F. (Elmira NY) Luderer Albert A. (Corning NY) Mansfield Gerald R. (Painted Post NY) Panzarino Joseph N. (Northboro MA), Radio frequency-induced hyperthermia for tumor therapy.
Groman Ernest V. (Brookline MA) Josephson Lee (Arlington MA) Lewis Jerome M. (Newton MA), Silanized biodegradable super paramagnetic metal oxides as contrast agents for imaging the gastrointestinal tract.
Weiss Keith D. (Cary NC) Carlson J. David (Cary NC) Duclos Theodore G. (Holly Springs NC) Abbey Kirk J. (Raleigh NC), Temperature independent magnetorheological materials.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.